Literature DB >> 8032345

Role of differentiation induction in action of purine antimetabolites.

G Weber1, Y Hata, N Prajda.   

Abstract

In cancer cells, particularly in leukaemic cells, guanylate biosynthesis is up-regulated as shown by the increased activities of IMP dehydrogenase, the rate-limiting enzyme of de novo GTP biosynthesis, and of the salvage enzyme, hypoxanthine-guanine phosphoribosyltransferase (HGPRT). In enzyme pattern-targeted chemotherapy, tiazofurin inhibits IMP dehydrogenase activity in cancer cells and allopurinol-induced high serum hypoxanthine levels inhibit HGPRT activity. A triad of responses was observed in the blast cells of patients treated with tiazofurin infusions: chemotherapy, induced differentiation, and down-regulation of c-Ki-ras and c-myc oncogenes. Tiazofurin was synergistic in cytotoxicity and in causing differentiation with ribavirin, retinoic acid, and gemcitabine [corrected]. Induced differentiation plays an important role in the overall impact of antipurine agents.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8032345     DOI: 10.1007/bf01880659

Source DB:  PubMed          Journal:  Pharm World Sci        ISSN: 0928-1231


  16 in total

1.  Induction of erythroid differentiation and modulation of gene expression by tiazofurin in K-562 leukemia cells.

Authors:  E Olah; Y Natsumeda; T Ikegami; Z Kote; M Horanyi; J Szelenyi; E Paulik; T Kremmer; S R Hollan; J Sugar
Journal:  Proc Natl Acad Sci U S A       Date:  1988-09       Impact factor: 11.205

2.  Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.

Authors:  J A Sokoloski; O C Blair; A C Sartorelli
Journal:  Cancer Res       Date:  1986-05       Impact factor: 12.701

Review 3.  Biochemical strategy of cancer cells and the design of chemotherapy: G. H. A. Clowes Memorial Lecture.

Authors:  G Weber
Journal:  Cancer Res       Date:  1983-08       Impact factor: 12.701

4.  Biochemically directed therapy of leukemia with tiazofurin, a selective blocker of inosine 5'-phosphate dehydrogenase activity.

Authors:  G J Tricot; H N Jayaram; E Lapis; Y Natsumeda; C R Nichols; P Kneebone; N Heerema; G Weber; R Hoffman
Journal:  Cancer Res       Date:  1989-07-01       Impact factor: 12.701

Review 5.  Tiazofurin: biological effects and clinical uses.

Authors:  G Tricot; H N Jayaram; G Weber; R Hoffman
Journal:  Int J Cell Cloning       Date:  1990-05

6.  Biochemical mechanisms of resistance to tiazofurin.

Authors:  H N Jayaram
Journal:  Adv Enzyme Regul       Date:  1985

7.  Action of the active metabolites of tiazofurin and ribavirin on purified IMP dehydrogenase.

Authors:  Y Yamada; Y Natsumeda; G Weber
Journal:  Biochemistry       Date:  1988-03-22       Impact factor: 3.162

8.  Synergistic cytotoxic effect of tiazofurin and ribavirin in hepatoma cells.

Authors:  Y Natsumeda; Y Yamada; Y Yamaji; G Weber
Journal:  Biochem Biophys Res Commun       Date:  1988-05-31       Impact factor: 3.575

9.  Down-regulation of c-myc and c-Ha-ras gene expression by tiazofurin in rat hepatoma cells.

Authors:  E Olah; Z Kote; Y Natsumeda; Y Yamaji; G Jarai; E Lapis; I Financsek; G Weber
Journal:  Cancer Biochem Biophys       Date:  1990-04

10.  A role for guanine ribonucleotides in the regulation of myeloid cell maturation.

Authors:  D G Wright
Journal:  Blood       Date:  1987-01       Impact factor: 22.113

View more
  1 in total

1.  Cloning and functional characterization of GMPR2, a novel human guanosine monophosphate reductase, which promotes the monocytic differentiation of HL-60 leukemia cells.

Authors:  Jia Zhang; Weiping Zhang; Dajin Zou; Guoyou Chen; Tao Wan; Minghui Zhang; Xuetao Cao
Journal:  J Cancer Res Clin Oncol       Date:  2003-03-01       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.